Author

Archibald Grant Prentice

Observed names: A. G. Prentice, ARCHIBALD G. PRENTICE, Archibald G Prentice, Archibald G. Prentice, Archibald Prentice, Grant Prentice

Observed institutions: University College Hospital, University of Bonn, University of South Florida, Royal Bournemouth Hospital, Royal Hospital for Children, The Royal Free Hospital, Southampton General Hospital, Royal South Hants Hospital, Derriford Hospital, Belfast City Hospital, Moffitt Cancer Center, Heartlands Hospital, Royal Marsden Hospital, Exeter Hospital, Exeter Hospital, Plymouth Hospital, University College London, Cardiff University, University of Birmingham

OpenAlex ID: A5111975794

Itraconazole Prevents Invasive Fungal Infections in Neutropenic Patients Treated for Hematologic Malignancies: Evidence From a Meta-Analysis of 3,597 Patients

2003 · Axel Glasmacher, Archibald Prentice, et al. · Journal of Clinical Oncology · 262

Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials

2009 · Keith Wheatley, Cassandra L. Brookes, et al. · British Journal of Haematology · 239

Attempts to Optimize Induction and Consolidation Treatment in Acute Myeloid Leukemia: Results of the MRC AML12 Trial

2009 · Alan K. Burnett, Robert K. Hills, et al. · Journal of Clinical Oncology · 230

A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies

1999 · Godfrey R. Morgenstern, Archibald G. Prentice, et al. · British Journal of Haematology · 199

ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL)

2005 · Sarah J. Richardson, Christine Matthews, et al. · Blood · 196

Making sense of itraconazole pharmacokinetics

2005 · Archibald Grant Prentice, Axel Glasmacher · Journal of Antimicrobial Chemotherapy · 144

The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial

2009 · Alan K. Burnett, Donald Milligan, et al. · British Journal of Haematology · 142

Relation of “lymphoid” phenotype and response to chemotherapy incorporating vincristine-prednisolone in the acute phase of Ph1 positive leukemia

1979 · George Janossy, Roger K. Woodruff, et al. · Cancer · 136

PDF

The plasminogen activator system in women with polycystic ovary syndrome

1998 · William U Atiomo, Susie A Bates, et al. · Fertility and Sterility · 126

PDF

The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA

2009 · Alan K. Burnett, Robert K. Hills, et al. · Blood · 118

PDF

Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis

2011 · Simone Lanini, Aoife C Molloy, et al. · BMC Medicine · 90

PDF

Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia

1995 · Archibald G. Prentice, David W. Warnock, et al. · Journal of Antimicrobial Chemotherapy · 74

p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism

2008 · Andrew J. Steele, Archibald G. Prentice, et al. · Blood · 69

Ultrasound criteria in the diagnosis of polycystic ovary syndrome (PCOS)

2000 · William U Atiomo, Sally Pearson, et al. · Ultrasound in Medicine & Biology · 69

Raised plasminogen activator inhibitor‐1 (PAI‐1) is not an independent risk factor in the polycystic ovary syndrome (PCOS)

2000 · William U. Atlorno, Robert Fox, et al. · Clinical Endocrinology · 68

The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment

2010 · Andrew J. Steele, Archibald G. Prentice, et al. · Blood · 64

Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies

2005 · Axel Glasmacher, Archibald Grant Prentice · Journal of Antimicrobial Chemotherapy · 52

2-phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells

2009 · Andrew J. Steele, Archibald G. Prentice, et al. · Blood · 47

Infections in patients taking Rituximab for hematologic malignancies: two-year cohort study

2013 · Simone Lanini, Aoife C Molloy, et al. · BMC Infectious Diseases · 28

PDF

Are women with polycystic ovary syndrome resistant to activated protein C?

2000 · William U Atiomo, John Condon, et al. · Fertility and Sterility · 26

Aberrantly activated anti‐apoptotic signalling mechanisms in chronic lymphocytic leukaemia cells: clues to the identification of novel therapeutic targets

2011 · R. Gitendra Wickremasinghe, Archibald G. Prentice, et al. · British Journal of Haematology · 24

PDF

Effect of anti-APO1 on Spontaneous Apotosis of B Cells in Chronic Lymphocytic Leukaemia: The Role of bel-2 and Interleukin 4

1995 · Tryfonia Mainou-Flower, Virginia A. Craig, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 24

Clinically Significant Responses Achieved with Romidepsin in Treatment-Refractory Cutaneous T-Cell Lymphoma: Final Results from a Phase 2B, International, Multicenter, Registration Study

2008 · Youn Kim, Sean Whittaker, et al. · Blood · 21

Acute Myelogenous Leukaemia Following Cytotoxic Therapy: Five Cases and Review

1982 · ALASTAIR G. SMITH, ARCHIBALD G. PRENTICE, et al. · QJM · 20

Romidepsin (depsipeptide) Induces Clinically Significant Responses in Treatment-Refractory CTCL: An International, Multicenter Study.

2007 · Youn H. Kim, Sunil Reddy, et al. · Blood · 9

Works count: 41

Citation count: 2,505

H-index: 22

I10-index: 24